LOS ANGELES--(BUSINESS WIRE)--Lundin Law PC (the “Firm”) announces that a class action lawsuit has been filed against Keryx Biopharmaceuticals Inc. ("Keryx" or the "Company") (Nasdaq: KERX) concerning possible violations of federal securities laws between February 25, 2016 and August 1, 2016 (the “Class Period”). Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm in advance of the October 3, 2016 lead plaintiff motion deadline.
No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.
According to the complaint, the Company made false and misleading statements and/or failed to disclose that Keryx was experiencing production-related difficulties in converting API to finished drug product; that the issue was resulting in decreased production yields of finished drug product; that the Company exhausted its reserve of finished drug product; and as a result of the above, Keryx’s statements about its business, operations and prospects were false and misleading and/or lacked a reasonable basis at all relevant times.
Lundin Law PC was created by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.